Literature DB >> 1647416

Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.

J Tanner1, G Tosato.   

Abstract

Expression of the human IL-6 gene in EBV-immortalized normal human B lymphocytes following retroviral-mediated transduction rendered these cells highly tumorigenic in athymic mice. The tumors were lymphomas composed of the originally inoculated human lymphoblastoid cells. Co-injection of IL-6 expressing EBV-immortalized cells with IL-6 nonexpressing control cells resulted in increased tumorigenicity of the IL-6 nonexpressing cells. The lymphoblastoid cells expressing IL-6 were indistinguishable from parental cell lines in morphology and in a variety of cell surface characteristics, and did not exhibit growth advantage over parental cell lines in vitro, such that increased tumorigenicity is unlikely to depend upon a direct oncogenic effect of IL-6 on the B cells. Rather, at high concentrations, IL-6 markedly inhibits human lymphoblastoid cell killing by IL-2-activated murine splenocytes in vitro, suggesting that IL-6-related tumorigenicity might depend upon IL-6 inhibiting cytotoxicity at the tumor site. Thus, production of IL-6 by tumor cells that results in natural killer cell dysfunctions illustrates a novel mechanism of tumor cell escape from immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647416      PMCID: PMC296025          DOI: 10.1172/JCI115283

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS.

Authors:  P I TERASAKI; J D MCCLELLAND
Journal:  Nature       Date:  1964-12-05       Impact factor: 49.962

2.  Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6).

Authors:  G Tosato; K B Seamon; N D Goldman; P B Sehgal; L T May; G C Washington; K D Jones; S E Pike
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

Review 3.  Evolution of tumours and the impact of molecular oncology.

Authors:  G Klein; E Klein
Journal:  Nature       Date:  1985 May 16-22       Impact factor: 49.962

Review 4.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma.

Authors:  M Rowe; C M Rooney; C F Edwards; G M Lenoir; A B Rickinson
Journal:  Int J Cancer       Date:  1986-03-15       Impact factor: 7.396

7.  Biochemical and biological analysis of human interleukin 6 expressed in rodent and primate cells.

Authors:  J E Tanner; N D Goldman; G Tosato
Journal:  Cytokine       Date:  1990-09       Impact factor: 3.861

8.  Stimulation of EBV-activated human B cells by monocytes and monocyte products. Role of IFN-beta 2/B cell stimulatory factor 2/IL-6.

Authors:  G Tosato; T L Gerrard; N G Goldman; S E Pike
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

9.  The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children.

Authors:  M Ho; R Jaffe; G Miller; M K Breinig; J S Dummer; L Makowka; R W Atchison; F Karrer; M A Nalesnik; T E Starzl
Journal:  Transplantation       Date:  1988-04       Impact factor: 4.939

10.  Regulation of interleukin 6 receptor expression in human monocytes and monocyte-derived macrophages. Comparison with the expression in human hepatocytes.

Authors:  J Bauer; T M Bauer; T Kalb; T Taga; G Lengyel; T Hirano; T Kishimoto; G Acs; L Mayer; W Gerok
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.

Authors:  Shannon Kenney
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

Review 2.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

3.  IFN-γ and other serum cytokines in head and neck squamous cell carcinomas.

Authors:  F Bussu; C Graziani; R Gallus; A Cittadini; J Galli; E DE Corso; G DI Cintio; M Corbi; G Almadori; A Boninsegna; G Paludetti; A Sgambato
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-04       Impact factor: 2.124

4.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Fabio D'Antona; Ada-Maria Florena; Emanuele La Spada; Angela Terranova; Melchiorre Cervello; Natale D'Alessandro; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

5.  Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia.

Authors:  Friso G J Calkoen; Carly Vervat; Else Eising; Lisanne S Vijfhuizen; Peter-Bram A C 't Hoen; Marry M van den Heuvel-Eibrink; R Maarten Egeler; Maarten J D van Tol; Lynne M Ball
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

6.  Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.

Authors:  Gregory K Hong; Margaret L Gulley; Wen-Hai Feng; Henri-Jacques Delecluse; Elizabeth Holley-Guthrie; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.

Authors:  Gregory K Hong; Pawan Kumar; Ling Wang; Blossom Damania; Margaret L Gulley; Henri-Jacques Delecluse; Peter J Polverini; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Cytokine production in the immune response to murine gammaherpesvirus 68.

Authors:  S R Sarawar; R D Cardin; J W Brooks; M Mehrpooya; R A Tripp; P C Doherty
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

9.  Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Dig Dis Sci       Date:  2008-07-26       Impact factor: 3.199

10.  Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.

Authors:  Alessio Mazzoni; Lorenzo Salvati; Laura Maggi; Manuela Capone; Anna Vanni; Michele Spinicci; Jessica Mencarini; Roberto Caporale; Benedetta Peruzzi; Alberto Antonelli; Michele Trotta; Lorenzo Zammarchi; Luca Ciani; Leonardo Gori; Chiara Lazzeri; Andrea Matucci; Alessandra Vultaggio; Oliviero Rossi; Fabio Almerigogna; Paola Parronchi; Paolo Fontanari; Federico Lavorini; Adriano Peris; Gian Maria Rossolini; Alessandro Bartoloni; Sergio Romagnani; Francesco Liotta; Francesco Annunziato; Lorenzo Cosmi
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.